Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2019 | Treating younger MM patients: finding the optimal induction regimen

Joan Bladé • 17 May 2019
COMy 2019
Multiple Myeloma Bortezomib Carfilzomib Daratumumab Dexamethasone Lenalidomide

Joan Bladé, MD, PhD, from the Hospital Clinic of Barcelona, Barcelona, Spain, describes the current and future treatment regimens for the optimal induction of younger patients with multiple myeloma peritransplant. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Joan Bladé

Looking forward to ISA 2022
2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
How the amyloidosis treatment landscape has transformed in recent years
1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
Managing and treating renal impairment in multiple myeloma
3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
Amyloidosis classification and epidemiology
3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Joan Bladé • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Joan Bladé • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Joan Bladé • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Joan Bladé • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals